SUNSET, La., April 20, 2015 (GLOBE NEWSWIRE) -- According to Resolve, The National Infertility Association, infertility is defined as two or more recurrent miscarriages. Up to 20% of all pregnancies will end in miscarriage. Although there are many reasons for this loss, research has uncovered elevated homocysteine as a causative factor.
Homocysteine is a naturally occuring amino acid, that, when elevated, can lead to many health conditions including recurrent miscarriage. One of the most common reasons for high homocysteine is the MTHFR gene abnormality. Methylenetetrahydrofolate Reductase is the enzyme encoded for metabolizing folates and B vitamins from diet or supplements into the usable form needed to fuel the DNA methylation cycle. We now know that about 60% of the U.S. population has some variant of this enzyme deficiency, which inhibits the normal breakdown of folic acid and other forms of folate-leading to high homocysteine. For this reason, standard prenatal vitamins containing folic acid will not address the MTHFR defect.
The breakdown of homocysteine is folate-dependent, and requires a specific combination of diverse folates.
According to Dr. Lawrence Ginsberg, MD, Red Oak Psychiatry: "Studies have shown a positive correlation in the MTHFR polymorphisms and spontaneous abortion, neural tube defects, and neurogenerative disorders such as autistic spectrum disorders...with as much as a 5.5 fold increase in spontaneous abortion."
A 2000 study published in Obstetrics and Gynecology entitled Homocysteine and Folate Levels as Risk Factors for Recurrent Early Pregnancy Loss concluded: "Elevated homocysteine and reduced serum folate concentrations were risk factors for recurrent spontaneous early pregnancy losses." Furthermore, some studies have indicated as much as a 38% increase in poor pregnancy outcomes in women with high homocysteine.
About JayMac Pharmaceuticals
JayMac Pharmaceuticals, LLC, based in Sunset, Louisiana, is expanding its prescription folate product line to specifically address the needs of patients facing male and female infertility and high risk pregnancy due to genetic polymorphisms (MTHFR), high homocysteine, and low folate levels. The new folate product is projected to be available June 2015.
CONTACT: Angela Hall JayMac Pharmaceuticals 850-602-1617Source:JayMac Pharmaceuticals(EnLyte)